These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29489408)

  • 1. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.
    Joo I; Lee JM; Lee ES; Ahn SJ; Lee DH; Kim SW; Ryu JK; Oh DY; Kim K; Lee KB; Jang JY
    AJR Am J Roentgenol; 2018 May; 210(5):1059-1065. PubMed ID: 29489408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.
    Kim BR; Kim JH; Ahn SJ; Joo I; Choi SY; Park SJ; Han JK
    Eur Radiol; 2019 Jan; 29(1):362-372. PubMed ID: 29931561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT.
    Morgan DE; Waggoner CN; Canon CL; Lockhart ME; Fineberg NS; Posey JA; Vickers SM
    AJR Am J Roentgenol; 2010 Mar; 194(3):615-22. PubMed ID: 20173136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
    Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
    Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
    Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
    Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement.
    Joo I; Lee JM; Lee ES; Son JY; Lee DH; Ahn SJ; Chang W; Lee SM; Kang HJ; Yang HK
    Radiology; 2019 Nov; 293(2):343-349. PubMed ID: 31502935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
    Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
    Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
    Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
    Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.
    Tamm EP; Loyer EM; Faria S; Raut CP; Evans DB; Wolff RA; Crane CH; Dubrow RA; Charnsangavej C
    Abdom Imaging; 2006; 31(5):568-74. PubMed ID: 16465578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
    Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
    Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
    Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
    Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
    Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
    BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT.
    Park HS; Lee JM; Choi HK; Hong SH; Han JK; Choi BI
    J Magn Reson Imaging; 2009 Sep; 30(3):586-95. PubMed ID: 19711405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-risk features in potentially resectable colon cancer: a prospective MDCT-pathology agreement study.
    Santiago IA; Rodrigues ER; Germano AS; Costa AM; Manso RT; Gomes AP; Leichsenring CD; Geraldes VM
    Abdom Radiol (NY); 2016 Oct; 41(10):1877-90. PubMed ID: 27315073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative tumor restaging and resectability assessment of gastric cancers after chemotherapy: diagnostic accuracy of MDCT using new staging criteria.
    Joo I; Kim SH; Ahn SJ; Lee ES; Shin CI; Lee HJ; Yang HK
    Abdom Radiol (NY); 2017 Dec; 42(12):2807-2815. PubMed ID: 28643135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment.
    Cassinotto C; Cortade J; Belleannée G; Lapuyade B; Terrebonne E; Vendrely V; Laurent C; Sa-Cunha A
    Eur J Radiol; 2013 Apr; 82(4):589-93. PubMed ID: 23287712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
    Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
    Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.